Celltrion

Celltrion, a significant force in the Korean pharmaceutical business, did the unthinkable by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector. The company has successfully pioneered various unexplored areas, and it expects to continue its expansion as a global biopharmaceutical company with unique methods for small molecule medications and new companies such as the Ubiquitous healthcare platform business.

Celltrion hopes to become a global pharmaceutical firm that promotes health and welfare for all by developing next-generation biopharmaceutical and small-molecule pharmaceutical products.

Celltrion made history by introducing Remsima, the world's first antibody biosimilar, to the market. Remsima offers a larger range of therapy alternatives to more patients than ever before at a low cost. Remsima's effectiveness and safety have been demonstrated by the cumulative number of prescriptions and the results of long-term clinical trials, making it the world's first biosimilar medication trusted by pharmaceutical authorities and patients worldwide.

Celltrion has secured nine pipelines for biosimilar pharmaceuticals used to treat autoimmune disorders. They created the Humira biosimilar CT-P17 in a high-concentration formulation for the global market, estimated to be worth KRW 25 trillion. CT-P17 has a competitive advantage over its competitors due to its high concentration.

Founded: 2002

Founder: Seo Jung-jin

Headquarters: Yeonsu-gu, Incheon, South Korea

Key people: Seo Jung-jin, Chairman, Kee Woo-sung, CEO

Website: https://www.celltrion.com/